Administration route |
None |
Dosage |
3.2E9~E12 virus particles |
Pts |
42 |
Age |
Adult, Older_Adult |
Outcome |
Exercise duration showed no significant differences at 4 weeks (P = .27) or 12 weeks (P = .47). The Ad5.hAC6 group experienced a significant increase in ejection fraction (EF) at 4 weeks (+6.0 EF units; P < .004), but not at 12 weeks (+3.0 EF units; P = .16). Basal left ventricular peak -dP/dt increased at 4 weeks (P < .03), and there was no increase in arrhythmias. The heart failure admission rate for the Ad5.hAC6 group was 9.5% (4 of 42), with a relative risk of 0.33 (95% CI, 0.08-1.36; P = .10) compared to the placebo group. |
Adverse reactions |
18/43(serious adverse event) |
References |
PMID:
27437887
|
|